Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by MrMugsyon Dec 05, 2020 4:22pm
270 Views
Post# 32044581

Goodman signals on the open market ...

Goodman signals on the open market ... Goodman makes purchases as himself and as Long Zone Holdings.
If you're long on this one, that's what you want to see from the CEO.
In addition to regular monthly purchases.
Signalling value ... IMO.

Filed 2020-12-04 18:08
 
Tx date 2020-12-04
$GUD
Knight Therapeutics Inc.
Goodman, Jonathan Ross
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$51,645
+9,800 vol
$5.27 each
496,236  
Filed 2020-12-04 09:46
 
Tx date 2020-12-03
$GUD
Knight Therapeutics Inc.
Long Zone Holdings Inc.
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$13,250
+2,500 vol
$5.30 each
21,645,933  
Filed 2020-12-04 09:45
 
Tx date 2020-12-03
$GUD
Knight Therapeutics Inc.
Long Zone Holdings Inc.
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$53,300
+10,000 vol
$5.33 each
21,643,433

<< Previous
Bullboard Posts
Next >>